Treasurer of the State of North Carolina Grows Holdings in Edwards Lifesciences Co. (NYSE:EW)

Treasurer of the State of North Carolina raised its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 5.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 324,376 shares of the medical research company's stock after acquiring an additional 16,280 shares during the period. Treasurer of the State of North Carolina owned approximately 0.05% of Edwards Lifesciences worth $24,014,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in EW. Crowley Wealth Management Inc. bought a new stake in Edwards Lifesciences in the 4th quarter worth approximately $26,000. Millstone Evans Group LLC bought a new stake in Edwards Lifesciences during the 4th quarter valued at approximately $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Edwards Lifesciences in the 4th quarter valued at $30,000. Roble Belko & Company Inc bought a new position in Edwards Lifesciences during the fourth quarter valued at approximately $46,000. Finally, Catalyst Capital Advisors LLC bought a new stake in Edwards Lifesciences in the fourth quarter worth $54,000. Institutional investors own 79.46% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Barclays upped their target price on Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. Truist Financial lowered their target price on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a research note on Friday, April 11th. Wolfe Research cut shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research report on Wednesday, February 12th. Piper Sandler raised their target price on Edwards Lifesciences from $70.00 to $73.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 12th. Finally, Morgan Stanley upped their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $78.55.

Edwards Lifesciences Stock Performance

Shares of NYSE EW traded up $0.85 during mid-day trading on Wednesday, reaching $71.61. 1,341,195 shares of the company were exchanged, compared to its average volume of 4,898,550. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $95.25. The company's 50-day simple moving average is $71.27 and its 200-day simple moving average is $70.76. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $42.10 billion, a P/E ratio of 10.27, a P/E/G ratio of 4.82 and a beta of 1.15.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, research analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 9,500 shares of the firm's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $67.96, for a total transaction of $645,620.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at $3,189,770.56. This trade represents a 16.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Bernard J. Zovighian sold 6,164 shares of Edwards Lifesciences stock in a transaction on Monday, March 10th. The stock was sold at an average price of $69.51, for a total transaction of $428,459.64. Following the completion of the transaction, the chief executive officer now owns 59,083 shares in the company, valued at approximately $4,106,859.33. The trade was a 9.45 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 72,353 shares of company stock valued at $5,197,442 over the last 90 days. Insiders own 1.29% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.